AxoGen, Inc. (NASDAQ:AXGN) Receives Consensus Rating of “Moderate Buy” from Analysts

AxoGen, Inc. (NASDAQ:AXGN) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $39.3750.

AXGN has been the topic of a number of analyst reports. Raymond James Financial reiterated an “outperform” rating and issued a $41.00 price target on shares of AxoGen in a research report on Monday, February 23rd. Wells Fargo & Company started coverage on shares of AxoGen in a research note on Thursday, February 19th. They issued an “overweight” rating and a $40.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AxoGen in a report on Monday, December 29th. Lake Street Capital upped their target price on shares of AxoGen from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Finally, Jefferies Financial Group increased their price target on shares of AxoGen from $29.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, December 4th.

Insider Activity

In other AxoGen news, Director Amy Mcbride Wendell sold 43,684 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $29.31, for a total value of $1,280,378.04. Following the transaction, the director directly owned 93,826 shares in the company, valued at approximately $2,750,040.06. This trade represents a 31.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph A. Tyndall sold 25,108 shares of AxoGen stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $30.98, for a total value of $777,845.84. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 263,600 shares of company stock worth $7,979,829. 2.78% of the stock is owned by company insiders.

Hedge Funds Weigh In On AxoGen

Several hedge funds have recently added to or reduced their stakes in AXGN. Future Financial Wealth Managment LLC bought a new stake in AxoGen during the 3rd quarter worth about $27,000. MCF Advisors LLC bought a new position in shares of AxoGen in the 4th quarter valued at about $30,000. Aquatic Capital Management LLC boosted its stake in shares of AxoGen by 287.8% in the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares during the last quarter. Arax Advisory Partners grew its position in shares of AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 819 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of AxoGen during the fourth quarter worth approximately $36,000. Institutional investors own 80.29% of the company’s stock.

AxoGen Trading Down 2.1%

Shares of AXGN stock opened at $28.55 on Monday. The firm has a fifty day moving average of $32.78 and a 200-day moving average of $25.72. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -83.97 and a beta of 0.98. AxoGen has a 52-week low of $9.22 and a 52-week high of $36.00. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.31 and a current ratio of 5.11.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Tuesday, February 24th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.01). AxoGen had a negative net margin of 6.97% and a negative return on equity of 13.44%. The business had revenue of $59.90 million for the quarter, compared to analyst estimates of $59.90 million. On average, equities research analysts forecast that AxoGen will post -0.29 earnings per share for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.